Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer.
Rescue intravesical therapies for BCG failure non-muscle invasive bladder cancer (NMIBC) patients remain a critical focus of ongoing research. Sequential intravesical gemcitabine and docetaxel (Gem/Doce) has shown safety and efficacy in 2 retrospective, single institution cohorts. This doublet has since been adopted as an intravesical salvage option at multiple institutions. We now report the results of a multi-institutional evaluation of Gem/Doce. Each institution retrospectively reviewed all patients treated with intravesical Gem/Doce for NMIBC between June 2009 and May 2018. Only patients with recurrent NMIBC and a history of prior BCG treatment were included in the analysis. If disease-free after induction, maintenance was instituted at the treating physician's discretion. Post-treatment surveillance followed AUA guidelines. Survival analysis was performed using the Kaplan Meier method and risk factors for treatment failure assessed with Cox regression models. Two hundred seventy-six patients (median age 73 years with 22.9 months median follow-up) received treatment. Nine patients were unable to tolerate a full induction course. One and two-year recurrence-free survival (RFS) were 60% and 46% and high grade RFS were 65% and 52%, respectively. Ten patients (10/276, 3.6%) had disease progression on TUR. Forty-three (43/276, 15.6%) patients went on to cystectomy (median 11.3 months from induction), of which 11 (11/276, 4.0%) had progressed to muscle-invasion. Analysis identified no patient, disease, or prior treatment-related factors associated with Gem/Doce failure. Intravesical Gem/Doce is well-tolerated and effective, providing a durable response in NMIBC patients with recurrence after BCG. Further prospective study is warranted.